Laurion Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Laurion Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-327,000	Closed	-$3.2M	–	1067
2019 Q4	$3.2M	Buy	+327,000	New	+$2.92M	0.02%	387
2018 Q1	–	Sell	-110,000	Closed	-$2.08M	–	1687
2017 Q4	$2.08M	Sell	110,000 -630,600	-85%	-$9.49M	0.01%	768
2017 Q3	$13M	Buy	740,600 +630,600	+573%	+$14.2M	0.06%	258
2017 Q2	$3.65M	Hold	110,000	–	–	0.02%	614
2017 Q1	$3.53M	Sell	110,000 -2,800	-2%	-$95.6K	0.03%	498
2016 Q4	$4.09M	Sell	112,800 -200,400	-64%	-$8M	0.04%	395
2016 Q3	$14.4M	Buy	313,200 +144,500	+86%	+$7.54M	0.14%	168
2016 Q2	$8.47M	Buy	+168,700	New	+$8.98M	0.13%	188
2016 Q1	–	Sell	-25,000	Closed	-$1.64M	–	1097
2015 Q4	$1.64M	Hold	25,000	–	–	0.02%	434
2015 Q3	$1.41M	Buy	+25,000	New	+$1.62M	0.02%	363
2014 Q3	–	Sell	-200,000	Closed	-$10.5M	–	390
2014 Q2	$10.5M	Buy	+200,000	New	+$10.2M	0.22%	132

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Laurion Capital Management's TEVA Position: Q4 2020 in Review

Laurion Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2020, closing a stake of 116,600 shares — an estimated $1.05M sold.

Laurion Capital Management first reported a position in TEVA in Q3 2015 and held it in 16 quarters. The position peaked at $40.8M in Q3 2016. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2020.

Laurion Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Laurion Capital Management sold 116,600 Teva Pharmaceuticals shares in Q4 2020, an estimated $1.05M.
Laurion Capital Management first reported a position in Teva Pharmaceuticals in Q3 2015 and held it in 16 quarters.
Laurion Capital Management's Teva Pharmaceuticals position peaked at $40.8M in Q3 2016.
450 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2020.

Based on Laurion Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.